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Background: Psychotropic drugs are widely used among old people with dementia but few studies have
described long-term treatment in this group of patients. The purpose of this study was to explore the long-term
use of psychotropic drugs in old people with dementia.
Methods: Data on psychotropic drug use, functioning in the activities of daily living (ADL), cognitive function and
behavioral and psychological symptoms were collected at baseline and six months later, using the Multi-
Dimensional Dementia Assessment Scale (MDDAS). The data were collected in 2005–2006. Detailed data about the
prescribing of psychotropic drugs were collected from prescription records. This study was conducted in 40 special-
ized care units in northern Sweden, with a study population of 278 people with dementia.
Results: At the start of the study, 229 of the participants (82%) were prescribed at least one psychotropic drug; 150
(54%) used antidepressants, 43 (16%) used anxiolytics, 107 (38%) used hypnotics and sedatives, and 111 (40%) used
antipsychotics. Among the baseline users of antidepressants, anxiolytics, hypnotics and sedatives and antipsychotics,
67%, 44%, 57% and 57% respectively, still used the same dose of the same psychotropic drug after six months.
Associations were found between behavioral and psychological symptoms and different psychotropic drugs.
Conclusion: Psychotropic drug use was high among people with dementia living in specialized care units and in
many cases the drugs were used for extended periods. It is very important to monitor the effects and adverse
effects of the prescribed drug in this frail group of people.
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The prescribing of drugs for old people is extensive and
often inappropriate [1]. A Swedish study of people living
in nursing homes shows that over 70% of the residents
had one or more potentially inappropriate prescription
according to quality indicators published by the Swedish
National Board of Health and Welfare [2].
The inappropriate use of drugs has been associated
with an increased risk of hospitalization among old
people [3] and studies show that up to 30% of hospital
admissions are directly connected to drug-related prob-
lems [4,5]. Older people are at increased risk of adverse
drug reactions, and older people with dementia are espe-
cially vulnerable [6].* Correspondence: maria.gustafsson@pharm.umu.se
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reproduction in any medium, provided the orOf particular concern is the high risk of adverse effects
among old people treated with psychotropic drugs.
These drugs are widely used among people with demen-
tia [7,8] despite the fact that this group is particularly at
risk of the adverse cognitive effects of drugs with anti-
cholinergic properties, such as antipsychotics and certain
antihistamines [8,9]. In addition, serious events such as
hospital admission or death are frequent following even
short-term use of antipsychotics among people with de-
mentia [10]. Many older people with dementia and neuro-
psychiatric symptoms can be withdrawn from chronic
antipsychotic treatment without deterioration, however,
some people could benefit from continuing their anti-
psychotic medication [11]. Benzodiazepines can cause
problems with impaired cognition [12], incident mobility
and ADL disability among old people [13]. Benzodiazepines
and other hypnotics and sedatives might also worsen sleep
apnea syndrome [14] and are therefore contraindicatedtral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Gustafsson et al. BMC Pharmacology and Toxicology 2013, 14:56 Page 2 of 9
http://www.biomedcentral.com/2050-6511/14/1/56among people with this condition. Sleep apnea syndrome is
common among people with dementia, with reported prev-
alence’s of around 50% and higher [15,16]. Antidepressants
also have several side-effects in individuals with dementia,
such as falls [17] and hyponatraemia [18]. Taken together,
many psychotropic drugs are considered inappropriate, or
should be used for a limited period only, or with caution
among older people [19].
Behavioral and psychological symptoms are common
among people with dementia [20]. Psychotropic drugs
are frequently used in nursing homes to treat these
symptoms, [21] despite their limited efficacy in this pa-
tient group [22,23]. Only a few studies have described
long-term psychotropic treatment among people with
dementia [21,24]. The aim of one of these studies was to
track changes in the prescribing patterns of antidepres-
sants, antipsychotics, anxiolytics and hypnotics over six
months among nursing homes residents in Australia
[24]. It was found that treatment with psychotropic
drugs was, in most cases, not adjusted over time.
We have previously reported data showing that the
use of antipsychotic drugs among people with dementia
living in specialized care units was high and the treat-
ment in many cases remained unchanged after six
months [25]. The study also showed that people who ex-
hibited aggressive behavior or passiveness, or had mild
cognitive impairment were at increased risk of being
prescribed antipsychotics [25]. The purpose of the present
study was to explore the prevalence, associated factors, in-
cluding behavioral and psychological symptoms, and long-
term use of all psychotropic drugs in old people with
dementia living in specialized care units. Previously re-
ported analyses of antipsychotic drugs in particular
[25] are not included.
Methods
Subjects and settings
Data for this study were taken from a research study
concerning the use of physical restraint [26]. This was
an intervention study conducted in 2005–2006, which
included 40 specialized care units for persons with de-
mentia in nine municipalities in northern Sweden. All
specialized care units in these areas were inventoried,
i.e. 99 units were contacted - and those units with the
highest prevalence of physical restraint use (≥ 20%)
were selected for inclusion in the study. Our study
population comprised 353 people with dementia, and
complete data from baseline and a six-month follow
up were obtained for 278 persons. Among these 278
people, the mean age was 82 years and 75% were
women. All had a dementia diagnosis, and 23% were
prescribed an anti-dementia drug. Records were in-
complete for 75 out of the 353 people because of in-
complete data (16), death (47) or dropout (12). Thestudy was approved by the Regional Ethical Review
Board in Umeå (registration number 02–105).
Procedures
The assessments were made using the Multi-Dimensional
Dementia Assessment Scale (MDDAS) [27]. The member
of staff who knew each resident best and were most in-
volved in their care performed the assessments based on
observations made over the preceding 7 days.
The scale measures, for example, functioning in the ac-
tivities of daily living (ADL), cognition, and behavior and
psychological symptoms. MDDAS also includes a registra-
tion of current drug prescription. The MDDAS has good
intra- and inter-rater reliability [27]. The ADL function
score ranges from 4–24, where a higher score indicates
greater ADL independence. This score is based on the pa-
tient’s ability to cope with hygiene, dressing, eating and
bladder and bowel control. Cognitive impairment was
measured using an assessment scale developed by Gott-
fries and Gottfries [28]. The scale comprises 27 items that
measure a person’s cognitive function. Scores of less than
24 are considered to indicate cognitive impairment, cor-
relating with a sensitivity of 90% and a specificity of 91%
[28] to the usual cut-off point, 24/30, of the Mini-mental
State Examination (MMSE) [29]. The scale is further
subdivided into three groups, mild cognitive impair-
ment (16–23), moderate cognitive impairment (8–15)
and severe cognitive impairment (0–7). The MDDAS con-
tains 25 behavioral items and 14 psychological symptom
items. Each item is rated on a three-point scale indicating
whether the symptom was present at least once a day, once
a week, or never during the one-week observation period.
These variables are dichotomized between at least once a
week and less than once a week in the present study.
The prescription records were collected at the start of the
study and six months later. The majority used an automated
multidose dispensing service where the person’s drugs are
dispensed in one-dose-unit bags for each dose occasion.
In this present study, the prescription records collected
earlier were searched in order to identify those patients
from the study population who were treated with psycho-
tropic drugs. All patients were listed according to age, sex,
and treatment with antidepressants (N06A), anxiolytics
(N05B), hypnotics and sedatives (N05C), and antipsy-
chotics (N05A). The WHO ATC (Anatomical Therapeutic
Chemical Index) classification system was used. Informa-
tion about dose and type of antidepressant, anxiolytics,
hypnotics and sedatives drugs was collected. Pro re nata
(PRN) drugs were not included, as information was lack-
ing about the actual use of these drugs.
Statistics and calculations
PASW Statistics 18 was used for data handling and stat-
istical calculations. A p-value of < 0.05 was considered
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model was constructed to find factors independently as-
sociated with psychotropic drug use. The behavioral and
the psychological symptom items of the MDDAS were
grouped and weighted (in each group every symptom
was multiplied by the calculated factor loading and then
added to the next symptom) according to a factor ana-
lysis previously described by Lövheim et al. [30]. The
factors were then normalized and included in a logistic
regression model that also included background vari-
ables (age, sex and level of cognitive impairment). As
many of the behavioral and psychological symptoms cor-
related strongly, the behaviors and symptoms were
tested in the regression model in a stepwise procedure,
where the behavior that had the strongest bivariate cor-
relation was included first, and all other behaviors and
symptoms were included subsequently one by one to see
if any of them contributed independently. The behavior
and symptom factors were: aggressive behavior, wandering
behavior, restless behavior, verbally disruptive/attention-
seeking behavior, passiveness, hallucinatory symptoms,
depressive symptoms, disoriented symptoms and re-
gressive/inappropriate behavior. Ultimately, all signifi-
cant behaviors and symptoms were included in a final
model, one for each drug group.
McNemars test without Yates correction was used to
compare the prevalence of symptoms at baseline and
follow-up, among people receiving various psychotropic
treatments.
Results
The characteristics of the study population and the preva-
lence of psychotropic drug use at the start of the study are
presented in Table 1. Two hundred and twenty-nine (82%)
of the people were prescribed at least one psychotropic
drug. One hundred and fifty (54%) used antidepressants,
131 (47%) used anxiolytics, hypnotics and sedatives, andTable 1 Characteristics of study population and
prevalence of psychotropic drug use at baseline
Cases, n 278
Women, n (%) 209 (75.2)
Mean age ± SD 82.0 ± 8.0
ADL score (4–24) mean ± SD 12.6 ± 5.4
Cognitive score (0–27) mean ± SD 10.7 ± 7.3
Antidepressant (N06A) use, n (%) 150 (54.0)
Anxiolytics, hypnotics and sedatives (N05B&C) use, n (%) 131 (47.1)
Anxiolytics drug (N05B) use, n (%) 43 (15.5)
Hypnotic and sedative drug (N05C) use, n (%) 107 (38.5)
Antipsychotic drug (N05A) use, n (%) 111 (39.9)
Any psychotropic drug use, n (%) 229 (82.4)
SD = Standard deviation, ADL = Activities of daily living.111 (40%) used antipsychotics. In addition, 74 people in
the study population (27%) were prescribed anxiolytics/
hypnotics/sedatives and an antidepressant drug simultan-
eously. Sixty-two people (22%) were prescribed anxio-
lytics/hypnotics/sedatives and an antipsychotic drug
simultaneously and 61 people (22%) an antidepressant
drug and an antipsychotic drug simultaneously. There
were 61 people (22%) who used three or more psycho-
tropic drugs concomitantly.
Furthermore, among antipsychotics (N05A), antide-
pressants (N06A), anxiolytics (N05B) and hypnotics and
sedatives (N05C), 64 people (23%) were prescribed in-
appropriate drugs, according to the National Board of
Health and Welfare (levomepromazine, clozapine, clo-
mipramine, hydroxyzine, diazepam, flunitrazepam and
propiomazine) [19]. Eight people used two inappropriate
drugs concomitantly.
Multiple logistic regression analyses
Multiple logistic regression analyses were performed for
three psychotropic drug classes: antidepressants (N06A),
anxiolytics (N05B) and hypnotics and sedatives (N05C)
(Table 2). Younger participants or people with moderate
cognitive impairment (compared to severe cognitive im-
pairment) were at increased risk of being prescribed an
antidepressant drug. There was no association between
antidepressant drug use and depressive symptoms or any
other BPSD factor.
Those who exhibited verbally disruptive/attention-
seeking behavior (a factor consisting of the following
symptoms: shrieks and shouts continuously, constantly
seeks attention of the staff, interrupted night’s sleep,
seeks help, disturbed and restless, complains) were at
increased risk of being prescribed an anxiolytic drug.
Three variables were associated with hypnotic and
sedative drug use: younger age, mild cognitive impair-
ment (compared to severe cognitive impairment) and
disoriented symptoms (a factor consisting of the follow-
ing symptoms: lies in other patients’ beds, take things
from other patients’ boxes and closets and undresses in
the dayroom).
A multiple regression analysis was also performed in-
cluding the symptom interrupted night’s sleep and back-
ground variables. No association was found between this
symptom and the prescribing of hypnotic and sedative
drugs (data not shown).
An earlier study explored the associations between an-
tipsychotics (N05A) and behavioral and psychological
symptoms in this study population [25].
Antidepressant drugs
Selective serotonin reuptake inhibitors (SSRI) were the
drugs mainly prescribed among the 150 persons who used
antidepressant drugs (Table 3). Citalopram accounted for








Male sex 0.727 0.381-1.385 0.332
Higher age 0.932 0.897-0.969 0.000
Moderate cognitive impairmenta 1.971 1.072-3.622 0.029
Mild cognitive impairmenta 0.933 0.460-1.894 0.848
Anxiolytics (N05B)
Male sex 0.522 0.181-1.505 0.229
Higher age 0.985 0.939-1.032 0.521
Moderate cognitive impairmenta 0.606 0.242-1.514 0.283
Mild cognitive impairmenta 1.331 0.509-3.481 0.560
Verbally disruptive/attention- 2.193 1.389-3.462 0.001
seeking behavior
Hypnotics and sedatives (N05C)
Male sex 1.769 0.917-3.413 0.089
Higher age 0.932 0.896-0.971 0.001
Moderate cognitive impairmenta 1.401 0.725-2.705 0.316
Mild cognitive impairmenta 3.627 1.685-7.810 0.001
Disoriented symptoms 1.545 1.169-2.041 0.002
Model Cox and Snell R2: 0.078, concordance between observed and predicted
value: 65.4% (antidepressants): 0.070/85.5% (anxiolytics): 0.138/69.9%
(hypnotics and sedatives). aCognitive score ranges from 0–27 points and a
score of less than 24 is considered to indicate cognitive impairment. The scale
is subdivided into three groups, 0–7 (severe cognitive impairment), 8–15
(moderate cognitive impairment) and 16–23 (mild cognitive impairment).
Severe cognitive impairment is reference category.
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line (20%) and mirtazapine (16%). At the start of the study,
150 persons (54%) were prescribed antidepressant drugs
(Figure 1). After six months, 100 out of these 150 (67%)
were still being treated with the same antidepressant drug
in the same dose. Seventeen of these 150 patients showed
changes in their prescriptions indicating an escalation of
treatment during the six-month period: four people had
another antidepressant added, six people had changed to
another antidepressant drug and seven had received an in-
creased dose. In total, 33 people had reduced their anti-
depressant treatment in various ways; 12 had a lower dose
or fewer antidepressant drugs, 21 had finished their anti-
depressant medication completely. This means that 86%
(129/150) were still being treated with antidepressant
drugs after 6 months. Among the 128 taking no anti-
depressant drug at the start of the study; eight people were
prescribed an antidepressant drug after six months. There
was a significant decrease in the proportion of people with
at least one of the three depressive symptoms (sad, crying
and anxious and fearful) from baseline to the six-monthfollow-up among people who were treated with antide-
pressants on both occasions (from 88/120 (73.3%) to 72/
120 (60.0%), p = 0.008).
Anxiolytic drugs
Concerning anxiolytics, 43 patients (15%) were pre-
scribed such a drug at the start of the study (Figure 2).
Oxazepam accounted for 70% of the anxiolytic prescrip-
tions followed by hydroxyzine (16%). After six months,
19/43 patients (44%) were still being treated with the
same drug and in the same dose. Five people showed
changes in their prescriptions indicating an escalation of
treatment during the six-month period, while 19 people
had reduced their anxiolytic treatment; 5 were on a
lower dose and 14 had ended their anxiolytic treatment,
meaning that 67% (29/43) were still being treated with
anxiolytic drugs after 6 months. After six months an
additional ten people were prescribed an anxiolytic drug.
There was no significant change from baseline to follow-
up in the proportion of people judged to be anxious and
fearful among those treated with anxiolytics on both oc-
casions (data not shown).
Hypnotic and sedative drugs
A total of 107 persons (38%) in the study population
used hypnotic and sedative drugs at the start of the
study (Figure 3). Propiomazine (28%) accounted for the
largest share of the hypnotic and sedative prescriptions.
After six months, 61 of these 107 (57%) were still being
treated with the same drug at the same dose. Of these
107 patients, there were changes in the prescriptions of
15 indicating an escalation in treatment during the six-
month period. Of these fifteen people, eight had another
hypnotic and sedative drug added, three changed to an-
other hypnotic and sedative drug and four were given an
increased dose. In total 31 people reduced their treat-
ment; eight had a lower dose or fewer hypnotic and
sedative drugs, 23 finished their treatment. In other
words, 78% (84/107) were still being treated with hyp-
notics and sedatives after 6 months. After six months an
additional four people were also prescribed a hypnotic
and sedative drug. There was no significant change from
baseline to follow-up in the proportion of people with
interrupted night’s sleep among those treated with hyp-
notics and sedatives on both occasions (data not shown).
Discussion
The prevalence of psychotropic drug use (82%) in the
study population is in line with or somewhat higher than
that reported previously among people with dementia
[21,31]. The use of more than one psychotropic drug
also seems to be common. This study reveals that many
people with dementia who live in specialized care units
appear to be on stable doses of psychotropic drugs for
Table 3 Characteristics of psychotropic drugs at the start of the study
Drug n (%) Dose, mean (mg) ± SD Range (mg) Dose, median (mg)
Antidepressants (N06A)
Citalopram 84 (52.5) 19.6 ± 6.1 10-40 20.0
Clomipramine 1 (0.6) 175.0 175.0
Escitalopram 1 (0.6) 10.0 10.0
Sertraline 32 (20.0) 68.0 ± 31.3 25-150 50.0
Mianserine 8 (5.0) 27.5 ± 10.3 10-40 30.0
Mirtazapine 26 (16.3) 30.6 ± 7.9 15-60 30.0
Venlafaxine 8 (5.0) 112.5 ± 56.7 75-225 75.0
Anxiolytics (N05B)
Hydroxyzine 7 (15.9) 32.9 ± 22.1 10-75 25.0
Diazepam 1 (2.3) 3.3 3.3
Oxazepam 31 (70.5) 24.0 ± 26.8 5-135 15.0
Alprazolam 4 (9.0) 2.6 ± 2.5 0.5-6 2.0
Buspirone 1 (2.3) 15.0 15.0
Hypnotics and sedatives (N05C)
Clometiazol 35 (26.3) 651.4 ± 273.7 300-1500 600.0
Flunitrazepam 15 (11.3) 0.7 ± 0.3 0.5-1 0.5
Propiomazine 37 (27.8) 33.4 ± 12.5 12-50 25.0
Zolpidem 19 (14.3) 6.4 ± 2.5 2.5-10 5.0
Zopiclone 27 (20.3) 6.9 ± 2.2 5-15 7.5
n = number of prescriptions, percent is calculated within each drug group.
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44% and 57% were being treated with the same dose of
the same antidepressant, anxiolytic or hypnotic/sedative
drug respectively. Also, 57% of the study population
were being treated with the same dose of the same anti-
psychotic drug after six months [25].
We found in the present study that more than every
second person was prescribed an antidepressant drug
(54%) and 67% of those who were prescribed antidepres-

















Figure 1 Antidepressants (N06A) – flow chart of participants from basame dose after six months. Put another way, for at least
33% changes were made concerning their antidepressant
treatment. These results differ from those reported by
O’Connor et al. where antidepressants in particular were
not adjusted over time. For example in only one out of
59 cases treated in that study was antidepressant medi-
cation stopped over the six-month period [24].
We found no association between antidepressant treat-
ment and depressive symptoms. This result also differs













































Figure 2 Anxiolytics (N05B) - flow chart of participants from baseline to six-month follow-up.
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possibly, these drugs were used also for other indications
besides depression – which the high prevalence of anti-
depressant drugs might indicate. In Sweden, SSRI is rec-
ommended as a first-line treatment for irritability, agitation
and anxiety among people with dementia [32]. It may also
be that people taking an antidepressant drug have no
current depressive symptoms because the drug treatment
had been successful, therefore few conclusions can be
drawn from a lack of association between depressive symp-
toms and antidepressants. It is much more worrying if per-
sons taking antidepressants are still depressed.
Unlike the situation for all other psychotropic classes,
properly monitored, long-term treatment with antidepres-
sants might be appropriate among people with dementia.
However, the very high prevalence of antidepressant drug
use in this study raises concern. Recent results show that
antidepressants have no antidepressant effects among
people with dementia, but they do entail an increased risk


















Figure 3 Hypnotics and sedatives (N05C) - flow chart of participants fdecrease in the prevalence of depressive symptoms from
baseline to follow-up among people who were treated with
antidepressants. However, considering the observational
nature of the data, these results have to be interpreted very
cautiously. True treatment effects cannot be differentiated
from any natural variation in symptoms over time.
Regarding anxiolytics, almost half the patients (44%)
were being treated with the same drug and in the same
dose after six months. This group includes some of the
benzodiazepines (diazepam, oxazepam and alprazolam).
These results are in agreement with an earlier study
where it was found that benzodiazepines were prescribed
with no clear indication for their use and were contin-
ued long-term in spite of the risks [34]. Benzodiazepines
should not be used for longer than 2–4 weeks by elderly
people because of their adverse effects, inducement of
dependency and limited efficacy when used continuously
[35]. Apart from the long-term use seen in this study, it
seems that in most cases a proper benzodiazepine
(short-acting) was prescribed.Study start
N=278
After 6 months 31


















rom baseline to six-month follow-up.
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and sedative drugs (38%) in this study warrants concern.
More than half the patients (57%) were being treated
with the same hypnotic and sedative drug in the same
dose after six months. Hypnotic and sedative drugs ad-
ministered regularly, every night for more than a month,
without re-examination are considered as an inappropri-
ate regimen among the elderly according to the Swedish
National Board of Health and Welfare [19]. The useful-
ness and safety of the long-term treatment of elderly
people with sleeping pills is not documented. A signifi-
cant tolerance can be developed to the hypnotic/sedative
effect, while the negative effect on psychomotor skills
and cognition remains. Intermittent treatment is there-
fore recommended. Flunitrazepam (long-acting benzodi-
azepine) should be avoided unless there are special
circumstances because of the high risk of side effects in
the elderly [19]. Also, given the high prevalence of
people with dementia who suffer from sleep apnea syn-
drome [15,16], treatment with benzodiazepines in this
population is in many cases contraindicated. Propioma-
zine and clometiazol were two commonly used drugs in
this study. They were previously manufactured and sold
by Swedish pharmaceutical companies and there is a
strong tradition of using these drugs in treatment in
Sweden. The use of propiomazine among older people,
especially those with dementia, is considered inappropri-
ate because of the risk of side effects such as extra pyr-
amidal symptoms. Clometiazol may be used for a short
time when urgent sedation is needed and if the patient
is adequately monitored [19].
No association was found between the symptom inter-
rupted night’s sleep and the prescribing of hypnotic and
sedative drugs, nor did we find any change in the preva-
lence of interrupted night’s sleep from baseline to six-
month follow-up among patients who were treated with
hypnotics/sedatives, or in the proportion of people who
were anxious and fearful among those taking anxiolytics.
This might possibly be a consequence of a tolerance of
benzodiazepines and similar drugs already developed at
baseline.
The regression analysis shows an association between
hypnotics/sedatives and the factor disoriented symptoms
and also an association between verbally disruptive/at-
tention-seeking behavior and anxiolytic drugs. The earl-
ier regression analysis with antipsychotics showed that
people who exhibited aggressive behavior or passiveness,
or had mild cognitive impairment were at increased risk
of being prescribed antipsychotics [25]. In another re-
cently published study we found that verbally disruptive/
attention-seeking behavior was associated with all psy-
chotropic drug classes, including antipsychotics [7]. Dis-
oriented symptoms and passiveness were also associated
with the use of antipsychotics in that study [7]. Takingthese findings together might indicate that psychotropic
drugs are being used for the wrong reasons in some
cases. For example, continuous shouting can be very
stressful for the staff. A Dutch study investigated associ-
ations between the use of psychotropic drugs and staff
distress, aspects of the physical environment and the pa-
tient’s neuropsychiatric symptoms, and found an associ-
ation between staff distress at patient’s agitation and the
use of antipsychotic and anxiolytic drugs [36]. Another
study from Taiwan found a correlation between the use
of psychotropic drugs and the severity of the caregiver’s
burden [37]. Concerning aggressive behavior, antipsy-
chotics have been shown to have some efficacy [38],
however, evidence of the efficacy of psychotropic drugs
for treating patients with verbally disruptive/attention-
seeking behavior is limited [23]. Psychotropic drugs with
their risk of potentially severe side effects should, how-
ever, only be used for the benefit of the person taking
them, taking into account both positive and negative ef-
fects. Staff distress cannot be regarded as a valid reason
for initiating such treatment.
In this study we have been able to describe the long-
term use of psychotropic drugs among people with de-
mentia at a detailed level. We found that many people
were treated with the same psychotropic drug in the
same dose after six months, which indicates long-term
treatment among this group of people. Given the signifi-
cant risk of adverse effects among people with dementia,
it is important that proper monitoring of drug therapy is
implemented to ensure the appropriate and safe use of
medication.
This study has some advantages. The pharmaceutical
registration was of high quality since the prescription re-
cords were searched in detail. We can also assume that
compliance was high since the vast majority of those
taking the drugs used an automated dose dispensing sys-
tem and the staff delivered the drugs.
The study also has some limitations that should be
considered. The data were collected in 2005–2006. We
cannot know if the prescribing has changed since then,
but there is no reason to believe that long-term treat-
ment with psychotropic drugs among people with de-
mentia has changed considerably.
The rather small number of people in the study popu-
lation may have meant that we did not discover some as-
sociations between the psychotropics and behavioral and
psychological symptoms. Data were registered at the
start of the study and six months later, but we know
nothing about what happened between those two dates,
for example whether dose reductions were tried and re-
versed because of aggravated symptoms. We do not
know the duration of psychotropic treatment at the time
of recruitment into the study, and we do not know the
background of the participants or if they had other
Gustafsson et al. BMC Pharmacology and Toxicology 2013, 14:56 Page 8 of 9
http://www.biomedcentral.com/2050-6511/14/1/56diseases. Some people might have bipolar disorder or
other chronic psychiatric illnesses where long-term
treatment of some psychotropic drugs might be appro-
priate when properly monitored.
Also, the selection of specialized care units was not
random but based on the prevalence of the use of phys-
ical restraint. It could be that people in these homes
have severe problems with BPSD and, therefore, receive
long-term treatment of psychotropic drugs to a greater
extent. However, comparing this population with an un-
selected material of persons living in specialized care
units for people with dementia (a subset of the material
presented in Lövheim et al. 2006) [39], also assessed
with the MDDAS, there were no differences concerning
the prevalence of aggressive behavior and verbally dis-
ruptive/attention-seeking behavior (data not shown). We
believe that the selection of participants does not affect
the main results of the study, but it should be borne in
mind when interpreting the results.
Conclusion
Psychotropic drug use among people with dementia liv-
ing in specialized care units was high and in many cases
the drugs seemed to be used for extended periods. It is
very important to monitor the effects and adverse effects
of the prescribed drug in this frail group of people.
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